NNC0491-6075 vs Solbinsiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
NNC0491-6075
Developed by Novo Nordisk
NCT05979428 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under quadruple-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a clinical or lipid outcome, and results have not yet been reported. Its registered primary outcome on ClinicalTrials.gov is "Part A (SAD): Number of treatment emergent adverse events (TEAEs)" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Solbinsiran
Developed by Eli Lilly
NCT05256654 · Phase 2 · completed
The study randomized 205 participants to three solbinsiran doses or placebo and masked both participants and investigators. Its primary endpoint was a laboratory biomarker rather than a hard clinical outcome, and the ApoB comparison was mixed across doses: significant for 400 mg but not for 100 mg or 800 mg, supporting moderate evidence rather than the highest grade.
Next expected readout: March 2027 · NCT07269210 (registry estimate)
Reported efficacy
Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 (Baseline, Day 180): LY3561774 100 mg -14.1% (Standard Error 4.98) | LY3561774 400 mg -24.3% (Standard Error 3.1) | LY3561774 800 mg -19% (Standard Error 3.35) vs Placebo -11.6% (Standard Error 3.65) (mixed)
Result source: NCT05256654
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | NNC0491-6075 | Solbinsiran |
|---|---|---|
| LDL-C, % change | —Not reported | -17.5% vs -12.7%−4.8 vs placeboNCT052566545 other results
|
| Non-HDL-C, % change | —Not reported | -27.3% vs -9.8%−17.5 vs placeboNCT052566545 other results
|
| ApoB, % change | —Not reported | -19% vs -11.6%−7.4 vs placeboNCT052566545 other results
|
| Lp(a), % change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
LDL-C, % change
- NNC0491-6075
- —Not reported
- Solbinsiran
- -17.5% vs -12.7%−4.8 vs placeboNCT05256654
5 other results
- -19.7% vs -8.7% NCT05256654
- -21% vs -12.7% NCT05256654
- -24% vs -8.7% NCT05256654
- -7.1% vs -12.7% NCT05256654
- -9.9% vs -8.7% NCT05256654
Non-HDL-C, % change
- NNC0491-6075
- —Not reported
- Solbinsiran
- -27.3% vs -9.8%−17.5 vs placeboNCT05256654
5 other results
- -31.5% vs -10.2% NCT05256654
- -27.6% vs -9.8% NCT05256654
- -33.1% vs -10.2% NCT05256654
- -13.5% vs -9.8% NCT05256654
- -19.8% vs -10.2% NCT05256654
ApoB, % change
- NNC0491-6075
- —Not reported
- Solbinsiran
- -19% vs -11.6%−7.4 vs placeboNCT05256654
5 other results
- -24.3% vs -11.6% NCT05256654
- -14.1% vs -11.6% NCT05256654
- -19.4% vs -9.5% NCT05256654
- -19.7% vs -9.5% NCT05256654
- -19.2% vs -9.5% NCT05256654
Lp(a), % change
- NNC0491-6075
- —Not reported
- Solbinsiran
- —Not reported
3-point MACE (% with event)
- NNC0491-6075
- —Not reported
- Solbinsiran
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
NNC0491-6075: no structured comparison results are available for Atherosclerotic Cardiovascular Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. NNC0491-6075: 0 of 4 rows · Solbinsiran: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Solbinsiran |
|---|---|
| Dropout rate | 8.5%800 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results5.2%400 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 10%100 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
| Discontinued due to AEs | 0%800 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results1.7%400 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 0%100 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
| Serious AEs | 3.4%800 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results5.2%400 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 3.3%100 mg NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
| Most frequent reported AEs | 800 mg covid-19 3.4% (placebo 7%) hypertension 3.4% (placebo 3.5%) influenza 3.4% (placebo 0%) NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 show 2 more results400 mg covid-19 5.2% (placebo 7%) injection site reaction 5.2% (placebo 0%) nasopharyngitis 5.2% (placebo 5.3%) NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 100 mg covid-19 13.3% (placebo 7%) gastroenteritis 10% (placebo 5.3%) hypertension 6.7% (placebo 3.5%) NCT05256654 · Phase 2 · monotherapy · Atherosclerotic Cardiovascular Disease, Hypertriglyceridemia · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Solbinsiran
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0491-6075's landscape · Solbinsiran's landscape